Objective: The objective of this study was to determine the morphologic spectrum and risk category of gastrointestinal stromal tumour (GIST) and compare with overall patient survival.
Introduction
Gastrointestinal stromal tumours (GISTs) were initially believed to be of smooth muscle origin. [1] However, now, this theory has been replaced by the fact that these originate from cells of Cajal, the pacemakers of gut. [2] Many population-based studies in Western countries have been published regarding epidemiology and prognosis of GISTs. However, there are few studies available in literature to document the characteristics of GISTs in Asian countries, especially in Pakistan. [3] GIST-affected patients have vague symptoms and mostly are discovered incidentally. [1, 3, 4] Most GISTs arise sporadically, but a small proportion arises with other tumours, (Carney triad) familial GIST syndrome and neurofibromatosis type 1 (NF1). [4] Stomach is the most common site of GIST (approximately 60-70%). Followed by small intestine (20-30%), while <10% arise from oesophagus, colon, rectum, omentum and mesentery. Around 10-30% of GISTs fall in high-risk category. Omentum/peritoneum and liver are the most common sites of recurrence and metastasis. [2] The diagnosis of GIST is made on typical histologic features; however, it has to be confirmed by immunohistochemical (IHC) panel including CD117 (c-kinase receptor [Kit] ) and diagnosed on GIST (DOG1). CD 117 positivity is important for diagnosis of GIST as well as for
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J Cancer Allied Spec 2016;2(4):3 therapeutic reasons. Up to 95% are positive for CD117. [2] About 70% of GIST are positive for CD34. The current recommendation by the College of American Pathologists cancer protocols, regarding the behaviour of GIST, is their stratification into very low, low, intermediate, high and very high-risk groups. This grouping is based on assessing location of tumour, gross tumour size as well as mitotic count in 20 high-power fields (HPFs) Armed Forces Institute of Pathology criteria for risk assessment. [2, 5, 6] Majority (85%) of GISTs have mutations in the gene encoding the transmembrane tyrosine kinase receptor (KIT). Most GISTs which lack KIT mutations are wildtype (approximately 10%) or harbour mutations in platelet-derived growth factor receptor which is highly homologous with KIT. NF1-associated GISTs usually retain expression of succinate dehydrogenase. [4] Majority (about 80%) of gastric GISTs have low risk for malignancy. Duodenal GISTs are most often found in the second part of duodenum and about half of them have high risk for malignancy. GISTs of colon, anorectum, oesophagus, omentum and peritoneum represent a small percentage of all GISTs. Therefore, less is known about their biologic behaviour. [2, 7, 8] While evaluating excision specimen of GIST, clinical history and any neoadjuvant treatment details are essential. Prior morphological appearance (spindle vs. epithelioid) and CD117 expression should also be known, as this information may change treatment. [2, 7, 9] 
Materials and Methods
A total of 31 patients who underwent excision of GIST from January 2009 to January 2015, at Shifa International Hospital were evaluated, after approval from the institution research board and ethical committee. Cases were included, irrespective of age, gender and with or without neoadjuvant chemotherapy administration.
The data were analysed by SPSS 17. Mean ± standard deviation (SD) of quantitative variables like age was calculated. Frequency and percentage for variables such as gender, tumour site, tumour size, mitotic count, morphologic pattern, necrosis and risk categorisation were determined. IHC pattern of CD117, DOG1, ASMA, CKAE1/AE3 and S100, resection margin status, neoadjuvant chemotherapy administration and its effects were noted.
Results
Of 31 patients, 21 (67.7%) were male and 10 (32.3%) were female with male-to-female ratio of 2.1:1. Distribution according to the location of tumour was as follows: Gastric 13 (41.9%), extra visceral 6 (19.4%), small intestine 9 (29.0%), rectum 2 (6.5%) and pancreas 1 (3.2%). In cases of small intestine, jejunum/ileum was the site in 3 (9.7%) and duodenum in 2 (6.5%), while in 4 (12.9%) exact site in small intestine was not specified. CD117 was performed in 30 cases, of which 29 (93.5%) were positive and equivocal in 1 (3.2%). DOG1 was performed in 16 cases, of them 15 (48.4%) were positive and 1 (3.2%) was negative [ Figure 1 ]. CD34 was performed in 22 cases, of which 17 (54.8%) were positive, while negative in 5 (16.1%).
ASMA was performed in 16 cases, of which 7 (22.6%) were positive and 9 (29%) were negative. S100 was performed in 13 cases, of which 3 (9.7%) were positive and 10 (32.3%) were negative. CKAE1/AE3 was performed in only four cases, and all were negative. Desmin was performed in one case, which was negative.
Neoadjuvant chemotherapy was given in 11 cases was available in 21 patients. 7 patients (22.5%) lost to follow-up. 8 (25%) had recurrence and 4 (12.9%) died.
Discussion
DeMatteo et al. reported GIST distribution to be 54% in stomach, 16% in rectum and 15% in small intestine. [1, 10] In DeMatteo et al. study, less than one-third of tumours were ≤5 cm. >2/3 rd of our tumours, i.e., 80.6% were >5 cm in greatest tumour dimension. Postsurgically, negative margins were reported in 81% of cases.
[10] While we had negative resection margins in 51.6%, probably due to large proportion of high-risk category GIST in our study. Follow-up in this study had a median follow-up of 24 months and documented disease-specific survival in 69% at 1 year. 46% were alive, 29% free of disease, 50% died of disease and 33% had isolated local recurrence. [10] Zhao et al., 70% of cases had spindle cell morphology and 20-25% had epithelioid while rest of cases had mixed appearance. Up to 95% of them are positive for CD117. GISTs can be negative or minimally positive for CD 117 in <5% of cases. [6] We had 58.1% of cases of spindle cell morphology, 6.5% with epithelioid appearance and 6.5% had mixed morphology. The variation is likely due to nondocumentation of morphological appearance in nine cases which make up to 29.9% of them. CD117 was positive in 93.5% and equivocal in 3.2%.
Miettinen et al. analysed 13 omental and 10 mesenteric GISTs with spindle cells or epithelioid cells; most of these tumours showed low mitotic activity. [11, 12] Reith et al. had analysed 48 GISTs of abdominal soft tissues, with the range of morphological features including purely epithelioid cells to those composed of spindle morphology as well some cases exhibiting mixed pattern. We had six extra-visceral cases, with four of them exhibiting spindle cell morphology while in two cases, pattern was not documented. Miettinen et al. had documented that omental and mesenteric GISTs were typically positive for CD117. [12] Reith et al. tumours expressed CD117 in 100%. [13] <5% of extraintestinal GIST are negative for CD117. [14] All of our six cases were positive for CD117.
Data regarding survival of patients with adjuvant Imatinib therapy are limited. The median follow-up period was 54 months with observation that 92% of patients receiving 36 months of therapy were alive as compared to 82% alive for patients receiving 12 months. In recent larger institutional studies, a significant portion of GISTs had low to very low-risk chance of recurrence. [15] [16] [17] Mucciarini et al. studied 124 GIST cases including 47% of high-risk cases. They observed 5-year disease-free survival rates after complete resection was 94%, 92%, 100% and 40% for patients at very low, low, intermediate and high risk, respectively. [3] Of 31 analysed cases in our study, 71% GISTs were of high-risk category, 16.1% in intermediate risk and 9.7% in very low risk while 3.2% had very low risk. 21 patients (67.7%) lost follow-up. 7 patients (22.5%) are asymptomatic, 1 (3.2%) had recurrence and 2 (6.5%) died. One (3.2%) of the asymptomatic patient received no further treatment after surgery. Patients who died and the one who had recurrence had GIST of high-risk group.
Surgical management of GISTs has been considered the most effective therapy. For locally advanced and metastatic GIST, Imatinib has been initiated. [17] [18] [19] [20] DeMatteo et al. concluded that although complete resection is associated with good outcome, it is not sufficient treatment. It had been observed that complete resection of GIST with adjacent organs, if required, should be performed. [10] 
Conclusion
Majority of cases diagnosed at our centre were gastric in origin followed by small intestine, and as per risk categorisation, most were high risk. Patient survival with high-risk tumours was dismal. 
